Page last updated: 2024-09-05

erlotinib hydrochloride and ethylnitrosourea

erlotinib hydrochloride has been researched along with ethylnitrosourea in 1 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (ethylnitrosourea)	Trials (ethylnitrosourea)	Recent Studies (post-2010) (ethylnitrosourea)
4,353	786	3,033	2,376	1	313

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Costa, DB; Jänne, PA; Kobayashi, SS; Lau, CJ; Mushajiang, M; Oxnard, GR; Paweletz, CP; Rangachari, D; Shpilsky, JE; To, C; VanderLaan, PA	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and ethylnitrosourea

Article	Year
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11 Topics: Acrylamides; Alkylating Agents; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Ethylnitrosourea; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; Mutagenesis; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome	2019

Article

Year

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11

Topics: Acrylamides; Alkylating Agents; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Ethylnitrosourea; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; Mutagenesis; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome

2019